These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36165931)

  • 1. PD-L1 Expression in Triple-negative Breast Cancer-a Comparative Study of 3 Different Antibodies.
    Vlajnic T; Baur F; Soysal SD; Weber WP; Piscuoglio S; Muenst S
    Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):726-730. PubMed ID: 36165931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.
    Sun WY; Lee YK; Koo JS
    J Transl Med; 2016 Jun; 14(1):173. PubMed ID: 27286842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.
    Noske A; Ammann JU; Wagner DC; Denkert C; Lebeau A; Sinn P; Kreipe HH; Sommer U; Baretton G; Steiger K; Kiechle M; Hieke-Schulz S; Flores M; Roth W; Weichert W
    Histopathology; 2021 Mar; 78(4):567-577. PubMed ID: 32936950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients.
    Schmidt G; Guhl MM; Solomayer EF; Wagenpfeil G; Hammadeh ME; Juhasz-Boess I; Endrikat J; Kasoha M; Bohle RM
    Arch Gynecol Obstet; 2022 Nov; 306(5):1689-1695. PubMed ID: 35377046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
    Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
    Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies.
    Lawson NL; Dix CI; Scorer PW; Stubbs CJ; Wong E; Hutchinson L; McCall EJ; Schimpl M; DeVries E; Walker J; Williams GH; Hunt J; Barker C
    Mod Pathol; 2020 Apr; 33(4):518-530. PubMed ID: 31558782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer.
    Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
    PLoS One; 2021; 16(9):e0257860. PubMed ID: 34559865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
    Kriegsmann M; Roessler S; Kriegsmann K; Renner M; Longuespée R; Albrecht T; Loeffler M; Singer S; Mehrabi A; Vogel MN; Pathil A; Köhler B; Springfeld C; Rupp C; Weiss KH; Goeppert B
    BMC Cancer; 2019 Jan; 19(1):72. PubMed ID: 30646854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens.
    Noske A; Steiger K; Ballke S; Kiechle M; Oettler D; Roth W; Weichert W
    J Clin Pathol; 2024 Mar; 77(4):239-245. PubMed ID: 36669878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3.
    Pang JB; Castles B; Byrne DJ; Button P; Hendry S; Lakhani SR; Sivasubramaniam V; Cooper WA; Armes J; Millar EKA; Raymond W; Roberts-Thomson S; Kumar B; Burr M; Selinger C; Harvey K; Chan C; Beith J; Clouston D; O'Toole SA; Fox SB;
    Am J Surg Pathol; 2021 Aug; 45(8):1108-1117. PubMed ID: 34232604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the relationship between tumor-infiltrating lymphocytes and PD-L1 expression in triple negative breast cancer: Identifying optimal TILs cut-off value for pathologic reporting.
    Suwannaphoom K; Soontornsit S; Wiwatwarayos K; Seneetuntigul P; Julimasart P
    Ann Diagn Pathol; 2024 Jun; 70():152294. PubMed ID: 38513466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.
    Smith J; Robida MD; Acosta K; Vennapusa B; Mistry A; Martin G; Yates A; Hnatyszyn HJ
    Diagn Pathol; 2016 May; 11(1):44. PubMed ID: 27189072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer.
    Noske A; Wagner DC; Schwamborn K; Foersch S; Steiger K; Kiechle M; Oettler D; Karapetyan S; Hapfelmeier A; Roth W; Weichert W
    Breast; 2021 Dec; 60():238-244. PubMed ID: 34768219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression comparison and clinical significance of PD-L1 (22C3) and PD-L1 (SP142) in triple negative breast cancer].
    Zhang J; Yuan P; Lei HZ; Liu XY; Li X; Ying JM; Sun GY; Wang SL; Lyu N
    Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):260-267. PubMed ID: 35316876
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.
    Reisenbichler ES; Han G; Bellizzi A; Bossuyt V; Brock J; Cole K; Fadare O; Hameed O; Hanley K; Harrison BT; Kuba MG; Ly A; Miller D; Podoll M; Roden AC; Singh K; Sanders MA; Wei S; Wen H; Pelekanou V; Yaghoobi V; Ahmed F; Pusztai L; Rimm DL
    Mod Pathol; 2020 Sep; 33(9):1746-1752. PubMed ID: 32300181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study.
    Paliogiannis P; Lobrano R; Bella MA; Fara A; Uras MG; Pinna MA; Tedde A; Madonia M; Zinellu A; Cossu A
    Ann Diagn Pathol; 2024 Apr; 69():152267. PubMed ID: 38266544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
    Ahn SG; Kim SK; Shepherd JH; Cha YJ; Bae SJ; Kim C; Jeong J; Perou CM
    Breast Cancer Res Treat; 2021 Jul; 188(1):165-178. PubMed ID: 33770313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
    Yeong J; Tan T; Chow ZL; Cheng Q; Lee B; Seet A; Lim JX; Lim JCT; Ong CCH; Thike AA; Saraf S; Tan BYC; Poh YC; Yee S; Liu J; Lim E; Iqbal J; Dent R; Tan PH
    J Clin Pathol; 2020 Sep; 73(9):557-562. PubMed ID: 31969377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer.
    Lee SE; Park HY; Lim SD; Han HS; Yoo YB; Kim WS
    J Breast Cancer; 2020 Jun; 23(3):303-313. PubMed ID: 32595992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic significance of PD-L1 expression as a potential predictor of survival in gastric cancer].
    Sotnikova TN; Danilova NV; Polushkina TV; Malkov PG; Chayka AV; Khomyakov VM; Kalinin DV
    Arkh Patol; 2023; 85(4):18-23. PubMed ID: 37530186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.